Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [41] Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
    Rosas, Ivan O.
    Diaz, George
    Gottlieb, Robert L.
    Lobo, Suzana M.
    Robinson, Philip
    Hunter, Bradley D.
    Cavalcante, Adilson W.
    Overcash, J. Scott
    Hanania, Nicola A.
    Skarbnik, Alan
    Garcia-Diaz, Julia
    Gordeev, Ivan
    Carratala, Jordi
    Gordon, Oliver
    Graham, Emily
    Lewin-Koh, Nicholas
    Tsai, Larry
    Tuckwell, Katie
    Cao, Huyen
    Brainard, Diana
    Olsson, Julie K.
    INTENSIVE CARE MEDICINE, 2021, 47 (11) : 1258 - 1270
  • [42] Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
    Ivan O. Rosas
    George Diaz
    Robert L. Gottlieb
    Suzana M. Lobo
    Philip Robinson
    Bradley D. Hunter
    Adilson W. Cavalcante
    J. Scott Overcash
    Nicola A. Hanania
    Alan Skarbnik
    Julia Garcia-Diaz
    Ivan Gordeev
    Jordi Carratalà
    Oliver Gordon
    Emily Graham
    Nicholas Lewin-Koh
    Larry Tsai
    Katie Tuckwell
    Huyen Cao
    Diana Brainard
    Julie K. Olsson
    Intensive Care Medicine, 2021, 47 : 1258 - 1270
  • [43] CORTICOSTEROID TREATMENT RESPONSE IN HOSPITALIZED COVID-19 PATIENTS
    Williams, Stephanie
    Lattanzio, Natalia
    Walo, Richard
    Hamad, Karen
    Wiese-Rometsch, Wilhelmine
    Seaman, Joseph
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 87 - 87
  • [44] Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19
    Chauhan, Kinsuk
    Pattharanitima, Pattharawin
    Piani, Federica
    Johnson, Richard J.
    Uribarri, Jaime
    Chan, Lili
    Coca, Steven G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 77 - 77
  • [45] Hypocalcemia is associated with adverse outcomes in patients hospitalized with COVID-19
    Minasi, Alessandro
    Andreadi, Aikaterini
    Maiorino, Alessio
    Giudice, Luca
    De Taddeo, Sofia
    D'Ippolito, Ilenia
    de Guido, Ilaria
    Laitano, Rossella
    Romano, Maria
    Ruotolo, Valeria
    Magrini, Andrea
    Di Daniele, Nicola
    Rogliani, Paola
    Bellia, Alfonso
    Lauro, Davide
    ENDOCRINE, 2023, 79 (03) : 577 - 586
  • [46] Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19
    Chauhan, Kinsuk
    Pattharanitima, Pattharawin
    Piani, Federica
    Johnson, Richard J.
    Uribarri, Jaime
    Chan, Lili
    Coca, Steven G.
    AMERICAN JOURNAL OF NEPHROLOGY, 2022, 53 (01) : 78 - 86
  • [47] Hypocalcemia is associated with adverse outcomes in patients hospitalized with COVID-19
    Alessandro Minasi
    Aikaterini Andreadi
    Alessio Maiorino
    Luca Giudice
    Sofia De Taddeo
    Ilenia D’Ippolito
    Ilaria de Guido
    Rossella Laitano
    Maria Romano
    Valeria Ruotolo
    Andrea Magrini
    Nicola Di Daniele
    Paola Rogliani
    Alfonso Bellia
    Davide Lauro
    Endocrine, 2023, 79 : 577 - 586
  • [48] Effects of statins on clinical outcomes in hospitalized patients with COVID-19
    Martins-Filho, Paulo Ricardo
    Soares Barreto-Filho, Jose Augusto
    Sobral Sousa, Antonio Carlos
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 104 : 113 - 115
  • [49] Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
    Bhatt, Ankeet S.
    Jering, Karola S.
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Cunningham, Jonathan W.
    Rosenthal, Ning
    Signorovitch, James
    Thune, Jens J.
    Vardeny, Orly
    Solomon, Scott D.
    JACC-HEART FAILURE, 2021, 9 (01) : 65 - 73
  • [50] Association of renalase with clinical outcomes in hospitalized patients with COVID-19
    Safdar, Basmah
    Wang, Melinda
    Guo, Xiaojia
    Cha, Charles
    Chun, Hyung J.
    Deng, Yanhong
    Dziura, James
    El-Khoury, Joe M.
    Gorelick, Fred
    Ko, Albert, I
    Lee, Alfred, I
    Safirstein, Robert
    Simonov, Michael
    Zhou, Bin
    Desir, Gary, V
    PLOS ONE, 2022, 17 (03):